(Q51418735)

5 April 2018

title

Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients. (English)

1 reference

5 April 2018

0 references

1 reference

1 reference

2

1 reference

5 April 2018

Riccardo Ientile

11

1 reference

5 April 2018

Lucilla Parnetti

5

object named as

Lucilla Parnetti

1 reference

5 April 2018

author name string

Gaetano Gorgone

1

1 reference

5 April 2018

Nadia Ferlazzo

3

1 reference

5 April 2018

Giulia Parisi

4

1 reference

5 April 2018

Vincenzo Belcastro

6

1 reference

5 April 2018

Nicola Tambasco

7

1 reference

5 April 2018

Aroldo Rossi

8

1 reference

5 April 2018

Francesco Pisani

9

1 reference

5 April 2018

Paolo Calabresi

10

1 reference

5 April 2018

Daniela Caccamo

12

1 reference

5 April 2018

publication date

22 February 2012

1 reference

5 April 2018

published in

NeuroMolecular Medicine

1 reference

5 April 2018

volume

14

1 reference

5 April 2018

issue

1

1 reference

5 April 2018

page(s)

84-90

1 reference

5 April 2018

https://scigraph.springernature.com/pub.10.1007/s12017-012-8174-1

exact match

0 references

cites work

Screening for C677T and A1298C MTHFR polymorphisms in patients with epilepsy and risk of hyperhomocysteinemia

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Microtubule dysfunction precedes transport impairment and mitochondria damage in MPP+ -induced neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Agmatine effects on mitochondrial membrane potential and NF-κB activation protect against rotenone-induced cell damage in human neuronal-like SH-SY5Y cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Methylenetetrahydrofolate reductase C677T genotype and PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Modifications of the iron-neuromelanin system in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Methylation status and neurodegenerative markers in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Clinical course in Parkinson's disease with elevated homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Mitochondrial dysfunction and oxidative damage in parkin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Worldwide distribution of a common methylenetetrahydrofolate reductase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Homocysteine and redox signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12017-012-8174-1

Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy

21 January 2018

1 reference

12 December 2020

The effect of 677C-->T and 1298A-->C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects

1 reference

12 December 2020

Mitochondria, oxidative damage, and inflammation in Parkinson's disease

1 reference

12 December 2020

Neuropathy in Parkinson disease: prevalence and determinants

1 reference

12 December 2020

Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia

1 reference

12 December 2020

Cell death mechanisms in Parkinson's disease

1 reference

12 December 2020

Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurod

1 reference

12 December 2020

Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD

1 reference

12 December 2020

Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease

1 reference

12 December 2020

Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage

1 reference

12 December 2020

Coenzyme Q10: a review of its promise as a neuroprotectant.

1 reference

12 December 2020

Coenzyme Q treatment of neurodegenerative diseases of aging

1 reference

12 December 2020

10.1007/S12017-012-8174-1

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018